Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Kemwell has doubled its production area for manufacturing pharmaceuticals for companies in the US, EU and Japanese markets. The new factory in Uppsala makes it possible to optimise future expansion.
Subscribe to our email newsletter
Kemwell has increased its production capacity by expanding the production area from 16,000 to 31,000 square meters. The expansion not only makes it possible for the company to increase production of tablets, suppositories and capsules but will also allow it to expand into other product types.
Agneta Bergvall, CEO of Kemwell, said: “Our new pharmaceutical factory will be characterised as a highly automated and flexible facility in order to satisfy the high demands of our existing and future clients within the pharmaceutical business.
“The new facilities also allow for production of other formulations. The company expects production in the new facility to start during 2010. We are very happy that our owners have chosen to expand in Sweden. Our employees have extended experience and are highly competent in the area of large-scale production.”
Leo Fallgren, manager of business development for Kemwell, said: “The new facility is in accordance with the expansive stage of the company considering the discussions that are taking place with several international pharmaceutical companies. Now we can help our customers become even more competitive by assuming their need for fullscale production.
“At the same time we are expanding our analytical- and method development and stability studies as well as re-analysis of products for the EU market but manufactured outside EU.”